A Phase 2 interventional study of Lunsekimig and Placebo in Asthma, sponsored by Sanofi. Completed at 156 sites in 14 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-17.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Asthma by Sanofi — 3 open to participants now, 5 under way, 1 of them phase 3. Asthma · Sanofi.
Among the 37 studies in Asthma by Sanofi, this one is the 12th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2023, is one of 11 in phase 2, and was the 33rd registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →3 of the 37 studies in Asthma by Sanofi are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Canada, France and 3 more countries
Ages 6+
Sanofi · Sites in United States, Argentina, Brazil and 17 more countries
Ages 18+
Sanofi · Sites in United States, Argentina, Brazil and 13 more countries
Ages 2–5
By country, each count listing its studies:
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 685 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 450 across the 31 interventional studies, 144 across the 5 observational. Of the 32 that completed or were terminated, 14 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
2 of the studies in Asthma by Sanofi that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05097287SanofiStudy Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | 2027-03-16 |
| NCT06676319SanofiStudy of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma | 2027-06-21 |
Add all 2 to your calendar (.ics) → With an account.
Among the 37 studies in Asthma by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig in adult participants aged 18 to 80 years, (inclusive) with moderate-to-severe asthma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Dose 1 of lunsekimig (subcutaneous injection) according to established dosing interval 1
Drug: Lunsekimig
Participants will receive Dose 1 of lunsekimig (subcutaneous injection) according to established dosing interval 2
Drug: Lunsekimig
Participants will receive Dose 2 of lunsekimig (subcutaneous injection) according to established dosing interval 1
Drug: Lunsekimig
Participants will receive Dose 2 of lunsekimig (subcutaneous injection) according to established dosing interval 2
Drug: Lunsekimig
Participants will receive placebo (subcutaneous injection) according to established dosing intervals corresponding to Dose 1 and Dose 2
Drug: Placebo
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Annualized rate of asthma exacerbation events
Time frame: From baseline to week 48
Change from baseline in pre-bronchodilator (BD) FEV1
Time frame: From baseline to week 48
Change from baseline in post-BD FEV1
Time frame: From baseline to week 48
The absolute change in the percent predicted FEV1 from baseline (pre-BD and post-BD)
Time frame: From baseline to week 48
Proportion of participants with ≥ 0.5-point reduction in ACQ-5 score
ACQ-5 is Asthma control questionnaire assessing symptoms. Lower score shows better asthma control
Time frame: From baseline to week 48
Change from baseline in ACQ-5 score
Time frame: From baseline to week 48
Change from baseline in FeNO
Time frame: From baseline to week 48
Time to first asthma exacerbation
Time frame: From baseline to week 48
Annualized rate of severe asthma exacerbations requiring hospitalization or emergency room or urgent care visit
Time frame: From baseline to week 48
Average number of inhalations per day of short-acting beta 2-agoinst (SABA), Low dose ICS/formoterol or ICS/SABA for symptom relief
Time frame: From baseline to week 48
Change from baseline in St. George's Respiratory Questionnaire (SGRQ) scores
Disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Scores range from 0 to 100, with higher scores indicating more limitations.
Time frame: From baseline to week 48
Proportion of participants with ≥4-point improvement in SGRQ score
Time frame: From baseline to week 48
Change from baseline in Asthma Quality of Life Questionnaire Standardized for 12 years and older (AQLQ{S} +12) scores
Time frame: From baseline to week 48
Proportion of participants with ≥0.5-point improvement in AQLQ(S)+12 domain and total scores
Time frame: From baseline to week 48
Change from baseline in ACQ scores
Time frame: From baseline to week 48
Proportion of participants with ≥0.5-point reduction in ACQ-6 and ACQ-7 score
Time frame: From baseline to week 48
Serum lunsekimig concentrations
Time frame: From baseline to week 52
Anti-drug antibodies (ADA) against lunsekimig
Time frame: From baseline to week 52
Incidence of participants with treatment-emergent adverse events (TEAEs), including local reactions, adverse events of special interests (AESIs), serious adverse events (SAEs)
Time frame: From baseline to week 52
Showing the first 100 of 156 sites across 14 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Oct 2023 to primary completion in Feb 2026, 28 months.
Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 28 months is above that.
Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lunsekimig